Trends, variation, and clinical characteristics of recipients of antiviral drugs and neutralising monoclonal antibodies for covid-19 in community settings: retrospective, descriptive cohort study of 23.4 million people in OpenSAFELY

OBJECTIVE: To ascertain patient eligibility status and describe coverage of antiviral drugs and neutralising monoclonal antibodies (nMAB) as treatment for covid-19 in community settings in England. DESIGN: Retrospective, descriptive cohort study, approved by NHS England. SETTING: Routine clinical da...

Descripción completa

Detalles Bibliográficos
Autores principales: Green, Amelia C A, Curtis, Helen J, Higgins, Rose, Nab, Linda, Mahalingasivam, Viyaasan, Smith, Rebecca M, Mehrkar, Amir, Inglesby, Peter, Drysdale, Henry, DeVito, Nicholas J, Croker, Richard, Rentsch, Christopher T, Bhaskaran, Krishnan, Tazare, John, Zheng, Bang, Andrews, Colm D, Bacon, Sebastian C J, Davy, Simon, Dillingham, Iain, Evans, David, Fisher, Louis, Hickman, George, Hopcroft, Lisa E M, Hulme, William J, Massey, Jon, MacDonald, Orla, Morley, Jessica, Morton, Caroline E, Park, Robin Y, Walker, Alex J, Ward, Tom, Wiedemann, Milan, Bates, Christopher, Cockburn, Jonathan, Parry, John, Hester, Frank, Harper, Sam, Douglas, Ian J, Evans, Stephen J W, Goldacre, Ben, Tomlinson, Laurie A, MacKenna, Brian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9951378/
https://www.ncbi.nlm.nih.gov/pubmed/36936265
http://dx.doi.org/10.1136/bmjmed-2022-000276

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9951378/
https://www.ncbi.nlm.nih.gov/pubmed/36936265
http://dx.doi.org/10.1136/bmjmed-2022-000276

Ejemplares similares